The Challenge: Cardiac muscle damage frequently leads to advanced Heart Failure (HF), the inability of the heart to pump sufficient blood to and from the rest of the body.  HF is progressive and debilitating as patients experience a decline in physical and cognitive function with increased hospitalizations. Drugs, surgery, and devices are often insufficient to stop the decline and the prognosis is poor as 50% of patients die within 5 years of diagnosis. In the US, the prevalence of HF lies well above 5 million patients and will continue growing. It represents the most common cause of hospitalizations in adults over 65 years of age. The direct cost to treat HF lies above $35 billion per year.

The Solution: MateraCor’s TCMR – Trans-Catheter Myocardial Restoration – is a one-time procedure performed by an interventional cardiologist to stop and reverse the progression of HF that is not responding to drug treatment alone.  TCMR does not interfere with other therapies and may in fact be synergistic. The effect of TCMR is an increase in exercise capacity and cardiovascular fitness.  Clinical trials are designed to confirm that increased exercise capacity makes patients feel more energetic, carry out physical activities with less discomfort, and experience fewer decompensation and hospitalization events.